{"schema_version":"secwatch.filing_event.v1","accession":"0001999480-26-000022","form_type":"8-K","ticker":"ANRO","cik":"0001999480","company_name":"Alto Neuroscience, Inc.","filed_at":"2026-08-12T20:14:32+00:00","discovered_at":"2026-08-12T20:15:04.439411+00:00","generated_at":"2026-08-12T20:15:12.114521+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Alto Neuroscience Q2 net loss $27.6M; expands ALTO-207 with Phase 3 monotherapy trial","bullets":["Net loss $27.6M in Q2 2026 vs $17.7M year-ago; R&D expenses $22.1M vs $13.1M.","July 2026 offering raised ~$100M gross; pro forma cash ~$338M, runway through 2030.","ALTO-207 Phase 3 monotherapy TRD trial added; PACE-2 Phase 3 adjunctive to start early 2027; PACE-1 Phase 2b topline 2H 2027.","Nature Medicine PRIME-PRAXOL: pramipexole reduced anhedonia (SHAPS p=0.006, Hedges' g=0.62) in MDD/bipolar depression.","ALTO-300 Phase 2b MDD topline 1H 2027; ALTO-100 Phase 2b BPD topline mid-2027."],"urls":{"canonical":"https://secwatch.observer/filing/0001999480-26-000022","json":"https://secwatch.observer/filing/0001999480-26-000022.json","markdown":"https://secwatch.observer/filing/0001999480-26-000022.md","text":"https://secwatch.observer/filing/0001999480-26-000022.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1999480/000199948026000022/0001999480-26-000022-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1999480/000199948026000022/alto-20260812.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-08-12T20:15:12.114521+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}